Welcome to our dedicated page for Tenon Medical SEC filings (Ticker: TNON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Tenon Medical’s SEC disclosures can feel like wading through surgical manuals—clinical trial data, FDA updates, and complex revenue notes often hide in 200-page documents. If you need Tenon Medical insider trading Form 4 transactions before the market reacts or want the story behind catheter-to-cash burn ratios, the raw forms alone won’t do.
Stock Titan solves that problem. Our AI deciphers every Tenon Medical quarterly earnings report 10-Q filing, highlights cash runway and Catamaran System adoption, and pushes real-time alerts for Tenon Medical Form 4 insider transactions real-time. Prefer plain English? Click “AI Summary” to see Tenon Medical SEC filings explained simply—from clinical-study milestones in an 8-K to reimbursement commentary buried in the MD&A.
Here’s how investors use it daily:
- Monitor surgeon-director buys with Tenon Medical executive stock transactions Form 4
- Compare R&D spend across quarters with our Tenon Medical earnings report filing analysis
- Spot pivotal trial results via Tenon Medical 8-K material events explained
- Review pay packages inside the Tenon Medical proxy statement executive compensation
- Dive deep with a Tenon Medical annual report 10-K simplified overview that links each risk factor to real-world impact
Every form—10-K, 10-Q, 8-K, S-1, or Section 16—lands here seconds after EDGAR posts. Our expert layer adds context so you can focus on decisions, not deciphering medical jargon. That’s understanding Tenon Medical SEC documents with AI.
Nathaniel A. Grawey, Chief Commercial Officer of Tenon Medical (TNON), reported beneficial ownership on a Form 3. He directly holds 138,114 shares of common stock, which are stated to be subject to a vesting schedule and non-transferable, and has an indirect interest in 175,383 shares through SiVantage, Inc. SiVantage owns 710,300 shares and Grawey holds 24.69% of that company.
Tenon Medical, Inc. reported quarterly revenue of $564,000 and six‑month revenue of $1.29 million, down from $901,000 and $1.62 million a year earlier, driven by fewer procedures using The Catamaran System. Gross profit fell and margins compressed, while the company recorded a net loss of $2.769 million for the quarter and $6.385 million for the six months, contributing to an accumulated deficit of $75.1 million. Cash and cash equivalents totaled $7.846 million at June 30, 2025, bolstered by $6.2 million of net financing in the first half of 2025.
Management discloses substantial doubt about the company’s ability to continue as a going concern for the next 12 months and plans to seek additional capital. Subsequent events include the acquisitions of SImmetry (closed Aug 1, 2025) and SIMPL (closed Aug 4, 2025), which transfer IP and product assets for cash, shares and royalty arrangements; the transactions also include executive hires with equity compensation. The company reported a material weakness in internal controls related to segregation of duties.
Tenon Medical's Chief Innovation Officer, Wyatt D. Geist, filed a Form 3 reporting beneficial ownership related to an 08/01/2025 event. He directly holds 138,114 common shares (noted as subject to a vesting schedule and non-transferable) and has an indirect interest of 350,765 shares through SiVantage, Inc. SiVantage owns 710,300 shares and Geist holds a 49.38% equity interest in that company.
Tenon Medical acquired substantially all assets and intellectual property of SiVantage's SImmetry business and of SIMPL, including technologies for sacropelvic fixation and posterior sacroiliac implants. Consideration to SiVantage included $750,000 cash, 710,300 shares of common stock (with 473,533 shares held by Tenon for one year as indemnity security), tiered royalties and contingent payments, and potential earnout equity. Royalties for SImmetry start at 15% then drop to 10% (capped at $5.0 million); SIMPL royalties begin at 30% (reducing to 20% after aggregate payments exceed $20.0 million). SiVantage and two related executives together beneficially own 986,528 shares, about 12.5% of outstanding stock, and two SiVantage principals were appointed to Tenon management and received 138,114 shares each.
FAQ
What is the current stock price of Tenon Medical (TNON)?
What is the market cap of Tenon Medical (TNON)?
